Comments on: Comparative Effectiveness and Personalized Medicine

By: E&Y Beyond Borders Biotech Report 2010 — Canadian Biotech Data « The RIC Blog

Wed, 21 Jul 2010 11:36:51 +0000

[...] and payors are pushing comparative effectiveness, outcomes-based pricing models (where pharma reimburses payors for cost of treating non-responding [...]

By: E&Y Beyond Borders Biotech Report 2010 — Canadian Biotech Data « The Cross-Border Biotech Blog

Wed, 14 Jul 2010 15:01:23 +0000

[...] and payors are pushing comparative effectiveness, outcomes-based pricing models (where pharma reimburses payors for cost of treating non-responding [...]

By: BIO Panel on Comparative Effectiveness Research Notes “Silver Lining” of Personalized Medicine « The Cross-Border Biotech Blog

Tue, 04 May 2010 16:13:51 +0000

[...] were, however, optimistic about the role of personalized medicine in the CER implementation. Steve LaPierre expects it to be helpful, and Daniel Todd advocates using the reference to [...]

By: Biotech Trends at BIO 2010 « The Cross-Border Biotech Blog

Biotech Trends at BIO 2010 « The Cross-Border Biotech Blog — Wed, 28 Apr 2010 16:13:55 +0000

[...] Does “Comparative Effectiveness Research and the Government Role” or “Transforming Health Care Through Personalized Medicine” catch your eye? Check out the stories we’ve highlighted on Comparative Effectiveness and Personalized Medicine! [...]

By: Comparative Effectiveness and Personalized Medicine are “Part of the Same Question” Collins Confirms « The Cross-Border Biotech Blog

Tue, 06 Apr 2010 16:53:11 +0000

[...] Couldn’t have said it better myself. [...]

By: Personalized Medicine: The limits of Genomic Analysis « The RIC Blog

Personalized Medicine: The limits of Genomic Analysis « The RIC Blog — Tue, 23 Feb 2010 11:40:43 +0000

[...] bottom line: In an age when genomic sequences are becoming increasingly accessible, it should be reassuring to know that even your medical future is not written in stone. We [...]

By: Biotech Trends Update — Personalized Medicine: The Limits of Genomic Analysis « The Cross-Border Biotech Blog

Wed, 17 Feb 2010 19:19:44 +0000

[...] bottom line: In an age when genomic sequences are becoming increasingly accessible, it should be reassuring to know that even your medical future is not written in stone. We [...]

By: Biotech Trends Update: Costs Savings from Personalized Medicine Sought by PBMs, Employers, Pharma Face Legal and Privacy Hurdles « The Cross-Border Biotech Blog

Thu, 04 Feb 2010 18:22:38 +0000

[...] a solution is required. As I have been saying for over a year, personalized approaches to treatment have the potential to benefit all participants in the [...]

By: Personalized Medicine: The case for diagnostics focuses on cost and effectiveness « The RIC Blog

Fri, 22 Jan 2010 11:37:49 +0000

[...] observations (and I’d encourage you to read the whole thing) was this bullet pointing out the value of personalized medicine in addressing comparative effectiveness concerns: “Interest in molecular diagnostics is heating up. It’s one of the most attractive areas [...]

By: Biotech Trends Update — Personalized Medicine: The Case for Diagnostics Focuses on Cost and Effectiveness « The Cross-Border Biotech Blog

Wed, 20 Jan 2010 23:16:40 +0000